TSE:APS - Aptose Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$8.50
  • Forecasted Upside: 658.93 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
C$1.12
▲ +0.07 (6.67%)

This chart shows the closing price for APS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aptose Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APS

Analyst Price Target is C$8.50
▲ +658.93% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Aptose Biosciences in the last 3 months. The average price target is C$8.50, with a high forecast of C$12.00 and a low forecast of C$5.00. The average price target represents a 658.93% upside from the last price of C$1.12.

This chart shows the closing price for APS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Aptose Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/16/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/16/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/15/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/3/2022JonestradingReiterated RatingBuyC$5.00
4/1/2022Cantor FitzgeraldReiterated RatingOverweight
3/23/2022JonestradingReiterated RatingBuyC$8.00
3/23/2022HC WainwrightBoost Price TargetBuyC$12.00
12/14/2021HC WainwrightReiterated RatingBuyC$14.00
11/17/2021Cantor FitzgeraldReiterated RatingOverweight
11/12/2021HC WainwrightReiterated RatingBuyC$14.00
10/19/2020Cantor FitzgeraldReiterated RatingOverweight
9/22/2020Alliance Global PartnersReiterated RatingBuyC$12.00
5/23/2019Roth CapitalReiterated RatingBuy
3/1/2019Royal Bank of CanadaReiterated RatingOutperformC$6.00
12/3/2018HC WainwrightReiterated RatingBuyC$8.50
11/16/2018B. RileyReiterated RatingBuy
11/7/2018HC WainwrightReiterated RatingBuyC$8.50
10/23/2017Roth CapitalReiterated RatingBuy
9/7/2017HC WainwrightReiterated RatingBuy
(Data available from 8/16/2017 forward)

News Sentiment Rating

0.53 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/17/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/19/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/18/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/18/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/17/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/17/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/16/2022

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Aptose Biosciences logo
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Read More

Today's Range

Now: C$1.12
Low: C$1.07
High: C$1.12

50 Day Range

MA: C$1.06
Low: C$0.93
High: C$1.21

52 Week Range

Now: C$1.12
Low: C$0.90
High: C$3.91

Volume

4,702 shs

Average Volume

30,468 shs

Market Capitalization

C$103.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Aptose Biosciences?

The following Wall Street analysts have issued research reports on Aptose Biosciences in the last year: Cantor Fitzgerald, HC Wainwright, and Jonestrading.
View the latest analyst ratings for APS.

What is the current price target for Aptose Biosciences?

2 Wall Street analysts have set twelve-month price targets for Aptose Biosciences in the last year. Their average twelve-month price target is C$8.50, suggesting a possible upside of 658.9%. HC Wainwright has the highest price target set, predicting APS will reach C$12.00 in the next twelve months. Jonestrading has the lowest price target set, forecasting a price of C$5.00 for Aptose Biosciences in the next year.
View the latest price targets for APS.

What is the current consensus analyst rating for Aptose Biosciences?

Aptose Biosciences currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APS will outperform the market and that investors should add to their positions of Aptose Biosciences.
View the latest ratings for APS.

What other companies compete with Aptose Biosciences?

How do I contact Aptose Biosciences' investor relations team?

Aptose Biosciences' physical mailing address is 5955 Airport Rd Suite 228, MISSISSAUGA, ON L4V 1R9, Canada. The biotechnology company's listed phone number is +1-647-4799828. The official website for Aptose Biosciences is aptose.com. Learn More about contacing Aptose Biosciences investor relations.